Posted at 17:55h
by aveak
...how we use, disclose, and protect the information that we collect about you when you: Visit our website (http://aptevotherapeutics.com) and any other websites that link to this Policy (collectively, the...
Posted at 15:42h
by aveak
...a safer and more tolerable treatment for AML patients. Clinical Trials Phase 1b Expansion Trial: Design and Outcomes Trial Design Overview: Evaluated patients (aged ≥ 18 years) with AML at...
Posted at 18:54h
by aveak
...License and Use Aptevo Therapeutics Inc. (“Aptevo Therapeutics”) grants you a limited license to display the contents of this website on your computer and print, download and use the materials...
Posted at 18:52h
by aveak
...vivo (preclinical models) and reduced cytokine release in preclinical studies may improve tolerability in a clinical setting ADAPTIR and ADAPTIR-FLEX can be used to design therapeutics with multiple MOAs. First,...
Posted at 16:21h
by aveak
...is a multi-center, multi-cohort, open-label trial that will include six dose levels. Patients will be assigned to dose levels according to a 3+3 design paradigm. The trial will be conducted...
Posted at 01:12h
by aveak
Contact Us Aptevo Therapeutics – Headquarters 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Tel: 206-838-0500 Fax: 206-838-0503 info@apvo.com Investor Relations & Corporate Communications Miriam Weber Miller Tel: 206-859-6628 Millerm@apvo.com...
Posted at 13:37h
by aveak
...in Europe and the design and implementation of the subsequent registration-enabling studies for the compound. Prior to Takeda, he served as the clinical lead of clofarabine and its development in...
Posted at 16:42h
by aveak
...as a dual agonist bispecific antibody APVO603 has the potential to produce a synergistic or amplified response resulting in more robust T cell response View APVO603 Scientific Presentations Here: https://aptevotherapeutics.gcs-web.com/presentations...
Posted at 17:19h
by aveak
...with our unique anti-CD3 can be utilized to target addition solid tumor antigens with the potential to improve responses in additional solid tumor indications. View APVO442 Scientific Presentations Here: https://aptevotherapeutics.gcs-web.com/presentations...
